CDK4 and neoplasm: Concurrent PD-L1 upregulation by CDK4/6 inhibitors further complicates this interplay, suggesting that immune checkpoint blockade may counteract resistance by leveraging heightened tumor immunogenicity (Zhang et al., 2018).